Therapy by physician–pharmacist combination and economic returns for cancer pain management in China: a cost-effectiveness analysis
- 1Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China
- 2National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
- 3College of Pharmacy, Dali University, Dali, China
- 4Department of Pharmacy, Fuwai Central China Cardiovascular Hospital, Zhengzhou, China
A Corrigendum on
Therapy by physician–pharmacist combination and economic returns for cancer pain management in China: a cost-effectiveness analysis
by Lu X, Zhang L, Huang H, Wu X, Wang Z, Huang L, Li J, Yu H, Zhang H and Xiao J (2023). Front. Pharmacol. 14:1073939. doi: 10.3389/fphar.2023.1073939
In the published article, there is a missing Funding statement. The correct Funding statement appears below.
“The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The study was supported by Hunan Provincial Natural Science Foundation of 2021 (2021JJ31043); Changsha Natural Science Foundation of 2020 (kq2007039); 2020 National Geriatric Disease Clinical Medicine Research Center Appropriate Technology Promotion Project (XYYYJSTG-15); Parallel and Distributed Processing for the Stable Support Project of the National Defense Science and Technology Key Laboratory (WDZC20205500121); Key Research Project of Ningxia Hui Autonomous Region in 2021 (Major Project) (2021BEG01001); Degree & Postgraduate Education Reform Project of Central South University (2022JGB067)”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: cancer pain, physician-pharmacist, cost-effectiveness analysis, decision trees, economics
Citation: Lu X, Zhang L, Huang H, Wu X, Wang Z, Huang L, Li J, Yu H, Zhang H and Xiao J (2023) Corrigendum: Therapy by physician–pharmacist combination and economic returns for cancer pain management in China: a cost-effectiveness analysis. Front. Pharmacol. 14:1327256. doi: 10.3389/fphar.2023.1327256
Received: 24 October 2023; Accepted: 10 November 2023;
Published: 17 November 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Lu, Zhang, Huang, Wu, Wang, Huang, Li, Yu, Zhang and Xiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jian Xiao, YWRtYW5vYXNAMTYzLmNvbQ==